-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Goals and Initiatives for a Representative Clinical Trial in Terms of Diversity, Equity and Inclusion: Co-Operative Group Perspective

Scientific Workshop on Defining Goals and Utilizing Tools for Enhancing Diversity, Equity and Inclusion (DEI) in Clinical Trials in Hematology
Program: Scientific Workshops
Session: Setting Realistic Goals for DEI in Hematology Trials
Friday, December 8, 2023, 3:00 PM-3:55 PM

Alvaro J. Alencar, MD

Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL

Disclosures: Alencar: Epizyme: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Beigene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Lilly: Membership on an entity's Board of Directors or advisory committees, Research Funding; Dr Reddy: Honoraria; Genentech: Membership on an entity's Board of Directors or advisory committees; SeaGen: Membership on an entity's Board of Directors or advisory committees.

See more of: Setting Realistic Goals for DEI in Hematology Trials
See more of: Scientific Workshop on Defining Goals and Utilizing Tools for Enhancing Diversity, Equity and Inclusion (DEI) in Clinical Trials in Hematology
See more of: Scientific Workshops
<< Previous Presentation | Next Presentation